Edited by Alessandro Finazzi-Agr Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
E., Berger, D., Latzer, Y
As of mid-2025, retatrutide is not approved by the MHRA or any other regulatory authority, and all dosing information derives exclusively from clinical trial protocols
Stepita ME, Bain MJ, Kass PH
Sci Rep 14:6178